Business Context and Reporting Period
This Form 8-K filing by West Pharmaceutical Services, Inc. (WST) reports a corporate governance event dated December 9, 2024. The filing announces the election of a new director to the Board of Directors.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation arrangements.
Material Changes
- Board Composition: The Board of Directors increased in size to 12 members with the election of Janet Haugen.
- Committee Assignment: Ms. Haugen is expected to serve on the Audit Committee effective immediately.
Management Commentary and Compensation
Ms. Haugen, 66, brings over 20 years of experience at Unisys Corporation, where she served as Chief Financial Officer for more than 16 years, overseeing business transformation and corporate development. She previously served as a partner at Ernst & Young and currently sits on the boards of Bentley Systems, Juniper Networks, and CentralSquare Technologies.
Compensation Arrangements:
- Annual retainer: $100,000.
- Annual restricted stock unit grant: $220,000.
- Compensation will be prorated for the period of service.
- Eligible to participate in the Director Deferred Compensation Plan.
The filing states there were no arrangements or understandings between Ms. Haugen and any other person regarding her election, and no transactions have occurred between the Company and Ms. Haugen since the beginning of the last fiscal year.
Investor Verification Checklist
- Verify the effective date of Ms. Haugen's participation on the Audit Committee.
- Review the Company's most recent proxy statement (filed March 13, 2024) for full details on the Director Deferred Compensation Plan.
- Confirm the total number of directors on the Board is now 12.